Moreover, since the first study reporting the clinical benefit of afatinib in ERBB2-mutant lung adenocarcinoma in 2011 [33], accumulating evidence has consistently demonstrated its clinical activity against various ERBB2-altered human malignancies, including lung, breast, and gastric cancers [34,35]. Here, ERBB2 is linked to lung adenocarcinoma.